<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578939</url>
  </required_header>
  <id_info>
    <org_study_id>1890</org_study_id>
    <nct_id>NCT03578939</nct_id>
  </id_info>
  <brief_title>Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic Adenocarcinoma</brief_title>
  <acronym>LAPC-NGS-A/001</acronym>
  <official_title>Next Generation Sequencing di Cellule Tumorali Nell'Adenocarcinoma Pancreatico Localmente Avanzato</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients referring to the U.O .of Digestive Endoscopy of the Humanitas Hospital to&#xD;
      undergo EUS with biopsy in the pre-treatment evaluation of locally advanced pancreatic&#xD;
      adenocarcinoma, satisfying all the inclusion criteria and without any of the exclusion&#xD;
      criteria, will be enrolled.&#xD;
&#xD;
      Patients will then undergo endoscopic procedures (EUS with biopsy) provided by good clinical&#xD;
      practice in consideration of the suspected diagnosis for which they come to Investigator's&#xD;
      attention.&#xD;
&#xD;
      Biopsy will be performed using a histology needle (22 G, Acquire, Boston Scientific, MA,&#xD;
      United States). The obtained material will be processed in the Pathological Anatomy. A small&#xD;
      part of this will be sent to the NGS analysis.&#xD;
&#xD;
      At the time of preparation for the examination, the patients will be asked for blood&#xD;
      collection (10 ml of blood) in order to evaluate any circulating tumor cells that will be&#xD;
      identified by SmartBioSurface technique (Tethis S.p.A) and analyzed by appropriate molecular&#xD;
      markers and NGS.&#xD;
&#xD;
      The clinical evaluation of the patient will take place at 6 months from the date of the&#xD;
      procedure, through telephone contact and / or outpatient visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Isomatic genetic mutations will be evaluated in locally advanced naïve pancreatic adenocarcinoma in order to better understand the best way to treat patient.</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adequacy of samples obtained by biopsy - EUS guided with needles Acquire from 22G in providing the diagnosis,</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy EUS guided</intervention_name>
    <description>NGS Sequencing on Biopsy samples</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients belonging to the U.O. of Digestive Endoscopy of the Humanitas Hospital to&#xD;
        undergo EUS with biopsy in the pre-treatment evaluation of locally advanced pancreatic&#xD;
        adenocarcinoma.&#xD;
&#xD;
        At the time of preparation for the examination, patients will be asked for blood collection&#xD;
        (10 ml of blood) in order to evaluate any circulating tumor cells.&#xD;
&#xD;
        Patients will then be subjected to the endoscopic procedure (EUS with biopsy) provided for&#xD;
        by good clinical practice in consideration of the suspected diagnosis for which they come&#xD;
        to our attention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years,&#xD;
&#xD;
          -  Signature of informed consent,&#xD;
&#xD;
          -  Naïve patients with pancreatic adenocarcinoma (confirmed cito/ histologically), not&#xD;
             subjected to previous treatments,&#xD;
&#xD;
          -  Need to perform EUS with biopsy,&#xD;
&#xD;
          -  Life expectancy over 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with non-primary pancreatic tumors, pancreatic neuroendocrine tumors or&#xD;
             benign pancreatic masses&#xD;
&#xD;
          -  Patients who have already undergone cancer treatment of any kind&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Silvia Carrara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

